Attached files
| file | filename |
|---|---|
| EX-5.1 - EXHIBIT 5.1 - Ocuphire Pharma, Inc. | ex5_1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 21, 2014
Rexahn Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
DELAWARE
|
001-34079
|
11-3516358
|
|
(State or other jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
15245 Shady Grove Road, Suite 455
Rockville, MD
|
|
20850
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (240) 268-5300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8 – Other Events
| Item 8.01 | Other Events. |
On January 21, 2014, Rexahn Pharmaceuticals, Inc., a Delaware corporation (“Rexahn”), closed a registered direct offering of 19,047,620 shares of its common stock and warrants to purchase 4,761,905 shares of its common stock, which Rexahn sold in units consisting of one share of common stock and a five-year warrant to purchase 0.25 of a share of common stock at an exercise price of $1.28 per share of common stock for gross proceeds of $20,000,001 (the “Offering”). The Offering was previously announced in a Current Report on Form 8-K filed on January 15, 2014.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits |
| 5.1 | Opinion of Hogan Lovells US LLP. |
| 23.1 | Consent of Hogan Lovells US LLP (included in Exhibit 5.1). |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
REXAHN PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
Date: January 21, 2014
|
/s/ Tae Heum Jeong
|
|
|
|
Tae Heum Jeong
|
|
|
|
Senior Vice President of Finance & Chief Financial Officer
|
|
3